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Abstract
I In nt tr ro od du uc ct ti io on n: :   Adrenomedullin (ADM) is a vasopeptide with multiple actions in the
cardiovascular system and a potentially powerful tool in comparison to some of
the well-established unimodal biomarkers of risk stratification in myocardial infarc-
tion (MI). Previous studies on ADM in acute MI were based on single assessment.
Therefore the aim of the study was to examine the relation between ADM plas-
ma concentrations assessed at different time points following MI and outcomes.
M Ma at te er ri ia al l   a an nd d   m me et th ho od ds s: :   The study included 127 patients with acute MI treated
with percutaneous coronary intervention and 60 healthy individuals as controls.
Adrenomedullin concentration was assessed at baseline in all study subjects
and 48 h after admission in patients with MI. The primary endpoint consisted
of all-cause death, nonfatal myocardial infarction, stroke and the need of tar-
get vessel revascularization at 6-month follow-up.
R Re es su ul lt ts s: :   Mean ADM plasma concentration on admission was higher in patients
with MI than in controls (30.3 ﾱ14.3 pmol/l vs. 14.6 ﾱ4.7 pmol/l, p < 0.0001).
There was no significant difference between ADM concentration after 48 h 
(30.6 ﾱ12.3 pmol/l) and on admission. The primary endpoint occurred in 9.4%
of patients with MI. Multivariable analysis showed that ADM concentration at 
48 h after admission (OR = 2.121, 95% CI 1.180-3.810 for every increase of 
10 pmol/l, p = 0.012) was the only independent predictor of the primary endpoint. 
C Co on nc cl lu us si io on ns s: :   In patients with acute MI adrenomedullin plasma concentration
assessed at 48 h after admission, but not ADM concentration at baseline, is an
independent predictor of major adverse cardiovascular events at mid-term fol-
low-up.
K Ke ey y   w wo or rd ds s: :   myocardial infarction, percutaneous coronary intervention, adreno  -
medullin, outcomes.
Introduction
Despite invasive and medical treatment of myocardial infarction (MI)
there is a persistent risk of recurrent cardiovascular events [1]. Identifica-
tion of patients at risk of those incidents remains one of the most impor-
tant targets of MI management. Various cardiac biomarkers assessed on
admission or in the first days of hospitalization were proposed as useful
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stratification measures including markers of inflam-
mation, renal function, myonecrosis, vascular tone
or platelet function [2-5].
Adrenomedullin (ADM) is a vasopeptide with
multiple actions in the cardiovascular system. It was
originally isolated from human pheochromocytoma,
but subsequent studies discovered that endothe-
lial cells are likely to be the major source of circu-
lating ADM. It is a natriuretic and hypotensive pep-
tide influencing many processes such as systemic
haemodynamics, neurohormonal responses, inflam-
matory mediators, oxidative stress, and cellular pro-
liferation or growth [6]. Multimodal ways of action
make ADM a potentially powerful tool in compari-
son to some of the well-established unimodal bio-
markers [2-5]. Moreover, ADM is not only a marker
of cardiovascular status but exerts cytoprotective
actions [7, 8].
Studies on plasma ADM concentrations in rela-
tion to mid- or long-term major adverse cardiovas-
cular events in patients with acute MI are limited
[9-15]. Most of them were based on single ADM
assessment. There are no data about the relation
between time of sampling of ADM during the first
days of MI and outcomes. 
Therefore, the aim of the study was to assess
the relation between ADM plasma concentrations
assessed at different time points after admission
and outcomes in patients with acute MI. 
Material and methods
S St tu ud dy y   g gr ro ou up p
The study included 127 consecutive patients with
acute MI treated invasively (ST-elevation 75.6%,
mean  age  63.9  ﾱ12.0,  male  sex  72.4%)  and 
60 healthy controls (mean age 40.5 ﾱ7.7, male 
sex 71.7%) from the Warsaw region defined on the
basis of their personal history (no risk factors of
coronary artery disease), normal resting ECG and
negative exercise stress testing on a treadmill. 
Diagnosis of MI was made according to con-
temporary guidelines [16, 17]. Obtained information
consisted of medical history, vital status, angio-
graphic parameters and baseline laboratory param-
eters. Hypertension was defined as systolic blood
pressure > 140 mmHg or diastolic blood pressure 
> 90 mmHg or current antihypertensive treatment.
Diabetes mellitus type 2 was diagnosed according
to WHO criteria or if a patient was on hypogly-
caemic drugs [18]. Hyperlipidaemia was defined if
the total cholesterol level was > 5.2 mmol/l or low-
density lipoprotein (LDL) cholesterol level was > 3.4
mmol/l, or if the patient was treated with a lipid-
lowering drug. Previous MI was classified on the
basis of medical history records. Number of dis-
eased coronary arteries was based on the presence
of > 50% stenosis in any of the major coronary
arteries. All patients with MI underwent resting
echocardiography for the assessment of left ven-
tricular ejection fraction (LVEF) during the first 24 h
after admission for MI (after the invasive treatment)
using a Hewlett-Packard Sonos 2500 (Hewlett-
Packard, Andover, MA). 
The Local Ethics Committee of the Institute of
Cardiology, Warsaw, Poland approved the study pro-
tocol and all patients provided written informed
consent. 
A Ad dr re en no om me ed du ul ll li in n   a as ss sa ay y
Adrenomedullin concentration in plasma was
assessed by means of immunoradiometric assay
(Shionogi, Osaka, Japan) [19]. Blood was drawn from
the antecubital vein on admission (in all patients
with MI and controls) and after 48 h (in all MI
patients). The detection limit was 0.5 pmol/l, and
the working range was 1-300 pmol/l (coefficient of
variability < 15%).
P Pr ri im ma ar ry y   e en nd dp po oi in nt t
Primary endpoint consisted of all-cause death,
nonfatal MI, stroke and the need of target vessel
revascularization at 6 months follow-up. 
S St ta at ti is st ti ic ca al l   a an na al ly ys si is s
Baseline characteristics of study patients were
summarized in terms of frequencies and percent-
ages for categorical variables and by means and
standard deviations (SD) for continuous variables
with normal distribution. Categorical variables were
compared by either Fisher’s exact or χ2 test and
continuous variables by Student’s t-test or Mann-
Whitney U test for unpaired samples, when appro-
priate. Correlations were assessed by means of
Pearson’s r-test or Spearman’s rho-test, when
appropriate. Multivariable analysis was performed
with the use of stepwise logistic regression. All sig-
nificant variables from the univariable analysis
entered the multivariable stage. A p-value (two-
tailed) of < 0.05 was considered statistically signif-
icant and confidence intervals (CI) were 95%. All
data analyses were performed using SPSS version
15.0 software (SPSS Polska Sp. Z o.o., Cracow,
Poland). 
Results
A Ad dr re en no om me ed du ul ll li in n   c co on nc ce en nt tr ra at ti io on ns s   i in n   p pa at ti ie en nt ts s
w wi it th h   M MI I   a an nd d   c co on nt tr ro ol ls s
Adrenomedullin concentration on admission was
higher in patients with MI than in controls (30.3
ﾱ14.3 pmol/l vs. 14.6 ﾱ4.7 pmol/l, p < 0.0001) 
(Figure 1). In the MI group vasopeptide concentra-
tions did not change significantly in the first 48 h
from admission. The absolute and relative changesArch Med Sci 6, December / 2011 973
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of ADM concentration after 48 h in comparison to
baseline in patients with MI were –0.3 ﾱ13.2 pmol/l
and 9.5 ﾱ49.4% (in both cases p = NS).
A AD DM M   c co on nc ce en nt tr ra at ti io on ns s   a an nd d   M MI I   p pa at ti ie en nt ts s’ ’   
c ch ha ar ra ac ct te er ri is st ti ic cs s   o on n   a ad dm mi is ss si io on n
Baseline clinical, angiographic and laboratory char-
acteristics of MI patients in relation to plasma ADM
concentration on admission and after 48 h are pre-
sented in Table I. Adrenomedullin plasma concentra-
tion 48 h after admission correlated significantly with
the largest number of assessed parameters includ-
ing age, heart rate on admission, LVEF, as well as high-
sensitivity C-reactive protein (hs-CRP) and glucose
level on admission. In comparison, adrenomedullin
plasma concentration on admission correlated sig-
nificantly with LVEF as well as creatinine, hs-CRP and
glucose level on admission. 
P Pr re ed di ic ct to or rs s   o of f   o ou ut tc co om me e   i in n   p pa at ti ie en nt ts s   w wi it th h   M MI I
The primary endpoint occurred in 12 patients dur-
ing follow-up (9.4%). There were 6 deaths (4.7%), 
3 nonfatal myocardial infarctions (2.35%) and 3 tar-
get vessel revascularizations (2.35%). Patients with
the primary endpoint were older, more likely to have
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F Fi ig gu ur re e   1 1. .   Plasma concentration of ADM at different
time points (admission, 48 h) in patients with myocar-
dial infarction (grey bars) and controls (white bars).
Bars show 95% confidence interval for mean and
whiskers present standard deviation of the mean
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P Pa ar ra am me et te er r A AD DM M   o on n   a ad dm mi is ss si io on n    V Va al lu ue e   o of f   p p A AD DM M   a at t   4 48 8   h h    V Va al lu ue e   o of f   p p
[ [p pm mo ol l/ /l l   ( (S SD D) )] ] [ [p pm mo ol l/ /l l   ( (S SD D) )] ]
Male/female sex  30.7 (14.5)/29.2 (14.0) NS 30.1 (12.1)/31.7 (12.7) NS
History – no/yes
Hypertension   32.3 (14.4)/29.0 (14.0) 0.09 32.2 (12.5)/29.0 (12.0) NS
Diabetes 29.7 (13.3)/34.3 (19.8) NS 29.9 (12.3)/35.5 (11.9) NS
Hyperlipidaemia 32.6 (15.4)/27.8 (12.8) 0.06 31.4 (13.7)/29.7 (10.6) NS
MI 30.7 (14.7)/27.1 (10.7) NS 30.3 (11.7)/34.0 (18.0) NS
Current cigarette 28.2 (13.4)/29.3 (15.4) NS 28.7 (12.8)/28.4 (7.6) NS
Smoker – no/yes
C Co or rr r. .   c co oe ef ff f. . C Co or rr r. .   c co oe ef ff f. .
Age [years] 0.14 NS 0.22 0.03
HR on admission [beats/s] 0.06 NS 0.23 0.02
Systolic BP on admission [mmHg] –0.13 NS –0.16 NS
Diastolic BP on admission [mmHg] –0.10 NS –0.08 NS
Number of diseased coronary  –0.09 NS 0.11 NS
arteries – no. 
LVEF [%]  –0.29 0.002 –0.39 < 0.001
Troponin I [ng/ml] –0.13 NS –0.17 NS
Creatinine [ﾵmol/l] 0.30 0.001 0.18 0.08
hsCRP [mg/dl] 0.38 < 0.001 0.38 < 0.001
Glucose [mmol/l] 0.32 0.001 0.23 0.03
Total cholesterol [mmol/l] –0.18 0.05 –0.19 0.06
LDL cholesterol [mmol/l] –0.07 NS –0.05 NS
ADM – adrenomedullin, BP – blood pressure, HR – heart rate, hsCRP – high sensitivity C-reactive protein, LDL – low density lipoprotein, LVEF –
left ventricular ejection fraction, MI – myocardial infarction, SD – standard deviation
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a history of MI and less likely to have hyperlipi-
daemia than those without the primary endpoint
(Table II). They had a higher concentration of ADM
at 48 h, but not on admission in comparison to
patients without the events (Figure 2). There was
a significant increase of ADM concentration over
time in patients with the events (p = 0.01), but not
in those without the events. 
The multivariable analysis model including age,
history of MI, hyperlipidaemia and ADM concentra-
tion at 48 h showed that ADM concentration at 
48 h after admission was the only independent pre-
dictor of the primary endpoint (OR = 2.121, 95% CI
1.180-3.810 for every increase of 10 pmol/l, p = 0.012).
Discussion
We demonstrate that plasma ADM measured at
48 h after admission can be an independent pre-
dictor of mid-term major adverse cardiovascular
events. Although we cannot directly explain the
pathomechanism of that relation, we show that
ADM plasma concentration 48 h after admission
correlates with the largest number of baseline 
clinical and laboratory parameters. Those parame-
ters included markers of inflammation (hs-CRP 
on admission), cardiac dysfunction (LVEF) and
haemodynamic status (heart rate on admission),
P Pa ar ra am me et te er r W Wi it th h   p pr ri im ma ar ry y   e en nd dp po oi in nt t    W Wi it th ho ou ut t   p pr ri im ma ar ry y   e en nd dp po oi in nt t    V Va al lu ue e   o of f   p p
( (n n = =   1 12 2) ) ( (n n = =   1 11 15 5) )
Age [years] (SD) 66.1 (11.0) 63.7 (12.1) NS
Male sex, n (%) 12 (100) 80 (69.6) 0.04
History, n (%)
Hypertension  5 (41.7) 57 (49.6) NS
Diabetes  0 17 (14.8) NS
Hyperlipidaemia 3 (25.0) 60 (52.2) 0.05
MI 5 (41.7) 7 (6.1) 0.004
Current cigarette smoker, n (%) 1 (8.3) 12 (10.4) NS
HR on admission [beats/s] (SD) 78.1 (12.5) 73.8 (9.0) NS
Systolic BP on admission [mmHg] (SD) 151.1 (34.2) 137.4 (21.1) NS
Diastolic BP on admission [mmHg] (SD) 90.8 (26.8) 78.2 (10.9) NS
Number of diseased coronary arteries, n (SD) 1.83 (0.94) 1.51 (0.83) NS
LVEF [%] (SD) 44.3 (17.6) 51.2 (9.4) NS
ADM on admission [pmol/l] (SD)  33.2 (15.5) 30.0 (14.2) NS
ADM at 48 h [pmol/l] (SD) 44.3 (19.8) 29.7 (11.3) 0.004
Troponin I [ng/ml] (SD) 9.8 (26) 5.3 (11.8) NS
Creatinine [ﾵmol/l] (SD) 91.2 (36.9) 77.7 (25.7) NS
hsCRP [mg/dl] (SD)  1.3 (2.4) 0.7 (1.8) NS
Glucose [mmol/l] (SD) 8.6 (3.2) 7.2 (2.8) NS
Total cholesterol [mmol/l] (SD) 5.2 (0.6) 5.1 (1.2) NS
LDL cholesterol [mmol/l] (SD) 3.6 (0.9) 3.7 (2.6) NS
ADM – adrenomedullin, BP – blood pressure, HR – heart rate, hsCRP – high sensitivity C-reactive protein, LDL – low density lipoprotein, 
LVEF – left ventricular ejection fraction, MI – myocardial infarction, SD – standard deviation
T Ta ab bl le e   I II I. .   Baseline characteristics of MI patients with and without the primary endpoint
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F Fi ig gu ur re e   2 2. .   Plasma concentration of ADM at different
time points (admission, 48 h) in patients with (grey
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which suggests the vasopeptide’s multimodal way
of action and makes it a good candidate for a mark-
er of future adverse events.  
Previous studies on the relation between ADM
plasma concentration and events during follow-
up were based on a single sampling performed dur-
ing the hospitalization, but not on admission for
MI. In the study by Nagaya et al., plasma ADM on
day 2 was the only non-invasive variable to inde-
pendently predict mortality at 25 months follow-
up after MI [9]. Similar findings come from the small
study of Katayama et al., where plasma ADM con-
centration obtained at 24 h after the onset of MI
was the strongest predictor of 1-year mortality in
multivariate  analysis  [10].  In  contrast,  in  the
Richards et al. study, adrenomedullin assessed at
day 2 to 4 after MI discriminated patients in rela-
tion to death in univariate analysis, but in contrast
to N-terminal pro-brain natriuretic peptide it did not
provide independent predictive information on
death and left ventricular failure at 24 months fol-
low-up [11]. According to the authors, the results
might have been influenced by the fact that ADM
levels in heart failure presumably reflect a more sys-
temic or peripheral response to cardiac impairment
instead of the ventricular response itself (such as
for natriuretic peptides). However, in two recent
studies it was demonstrated that a mid regional
pro-ADM (MR-proADM) assessed after 3 to 5 days
in patients with ST-elevation myocardial infarction
or within 36 h in patients with non-ST-elevation
myocardial infarction is a powerful predictor of
adverse outcome and adds further prognostic infor-
mation over NT-proBNP and commonly used risk
scores [14, 15]. It is worth noting that in the latter
study MR-proADM concentrations assessed within
36 h from the onset of symptoms were a better pre-
dictor of outcome than the marker levels at dis-
charge [15]. Earlier sampling of ADM (up to 48 h
after the onset of symptoms) may be more justi-
fied than late assessment (after day 3) as most of
the initial studies reported peak ADM concentra-
tions in plasma to occur in the acute phase of MI
[20, 21].
Our results confirm the previous findings that
ADM concentration assessed in the first days after
admission is an independent predictor of clinical
outcome. We have also discovered that biomarker
levels on admission were of no predictive value for
outcomes in the studied group. At the same time
thre was no significant rise in ADM concentration
in plasma at 48 h after admission in patients with
MI in comparison to baseline. However, despite
a similar mean level of ADM concentration over
time in the whole studied group, there was an
increase in mean plasma ADM concentration in
time in MI patients who suffered from the major
adverse cardiovascular event during follow-up in
comparison to patients without the event, whose
mean ADM concentration remained unchanged
during the first 48 h after admission.  
The first limitation of our study is the fact that
despite being the largest study to date we were
unable to analyse the relation between ADM con-
centration and individual components of the pri-
mary endpoint. Secondly, although differences in
patients' age between the study group and controls
may be potentially considered as a confounding fac-
tor, previous studies showed no significant varia-
tions of ADM plasma concentration with respect to
sex and age [22].
We believe that ADM concentration at 48 h after
admission or its increase during the first days of
acute MI may be a good predictor of future out-
come beyond markers included in most of the cur-
rently used risk scores such as ejection fraction or
other biomarker levels. 
In conclusion, our study indicates that in patients
with acute MI, adrenomedullin plasma concen  -
tration  assessed  at  48  h  from  admission,  but 
not at baseline, is an independent predictor of 
major adverse cardiovascular events at mid-term 
follow-up. 
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